Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : to Compare Migraine Drugs Emgality, Nurtec ODT in Phase 4 Study

06/15/2021 | 07:59am EDT


© MT Newswires 2021
All news about ELI LILLY AND COMPANY
07/29ELI LILLY AND : FCA Upholds Award Of Compound Interest In Cefaclor Damages Appea..
AQ
07/29ELI LILLY AND : Lilly releases donanemab data that demonstrated relationship bet..
PR
07/29ELI LILLY AND : Incyte Get Expanded Emergency Use Approval for Baricitinib as Mo..
MT
07/29Eli Lilly, Kumquat Biosciences Form Cancer Collaboration
DJ
07/29ELI LILLY AND : FDA broadens existing emergency use of Lilly and Incyte's barici..
PR
07/29ELI LILLY AND : Unit, Kumquat Biosciences to Develop Molecules for Tumor Immunit..
MT
07/29Lilly, Incyte Get Emergency Use Authorization for Covid-19 Treatment as Monot..
DJ
07/29ELI LILLY AND : Unit, Kumquat Biosciences to Develop Molecules to Invoke Tumor I..
MT
07/29ELI LILLY AND : Lilly and Kumquat Biosciences Announce Collaboration to Discover..
PR
07/23ELI LILLY AND : (LLY) sees Significant Insider Selling Continuing
MT
More news
Financials (USD)
Sales 2021 27 265 M - -
Net income 2021 6 579 M - -
Net Debt 2021 11 244 M - -
P/E ratio 2021 33,6x
Yield 2021 1,35%
Capitalization 221 B 221 B -
EV / Sales 2021 8,53x
EV / Sales 2022 8,26x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 243,50 $
Average target price 241,90 $
Spread / Average Target -0,66%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY44.22%221 348
JOHNSON & JOHNSON9.42%453 418
ROCHE HOLDING AG12.49%335 069
PFIZER, INC.16.30%239 525
NOVARTIS AG-0.16%224 495
ABBVIE INC.8.54%209 951